Standard Medicine principal investigators will receive nearly $15 million over a four-year term from the National Institutes of Health (NIH) to study long COVID. Stanford is but one of 30 research teams involved with the imminent, nationwide, NIH-sponsored RECOVER (Researching COVID to Enhance Recovery) study. Established to identify risk factors involved with long COVID, as well as to help develop approaches to prevent and treat the condition, the study also seeks to better understand why some people experience the condition while others do not.  The Stanford Medicine trial site will enroll 900 COVID-19 survivors, including those complaining of ongoing symptoms that implicate long COVID.  The participants are monitored for four years.

The Condition

Studies reveal that anywhere from 10% to 30% of people who had acute SARS-CoV-2 cases experience symptoms that last one month or more. These symptoms can range from the somewhat mild to severe and include pain, headaches, fatigue, shortness of breath, anxiety and depression and many other indicators.

The Study

According to the NIH, the RECOVER study seeks to understand, prevent, and treat PASC, including Long COVID. “PASC” stands for post-acute sequelae of SARS-CoV-2 and is a term scientists are using to study the potential consequences of SARS-CoV-2 infection. For more details about RECOVER follow the link.Subscribe to the Trialsitenews “COVID-19” ChannelNo spam – we promise

Lead Research/Investigators

  • Upinder Singh, MD, professor of infectious diseases and geographical medicine and of microbiology and immunology
  • PJ Utz, MD, PhD, professor of immunology and rheumatology
  • Catherine Blish, MD, PhD, professor of infectious diseases
  • Yvonne Maldonado, MD, professor of pediatric infectious disease and of epidemiology and population health, as well as the Taube Professor of Global Health and Infectious Diseases

Link to Article



Submit a Comment